title: Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study.
abstract: Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-GD2murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human anti-mouse antibody (HAMA) to receive rituximab to ablate HAMA with or without low-dose maintenance chemotherapy until immunotherapy could resume. For the total of 101 study patients, 5-year PFS and overall survival (OS) rates were 33% ± 5% and 48% ± 5%, respectively. Among the 33 long-term progression-free survivors, 19 hadMYCNamplification, 19 had previously received anti-GD2immunotherapy plus isotretinoin (as first-line therapy), and 15 never received maintenance chemotherapy. In a multivariate analysis of prognostic factors, only absence of minimal residual disease in bone marrow after 2 cycles of immunotherapy and before initiation of isotretinoin or anti-HAMA therapy was significantly favorable for both PFS and OS. Therefore, long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-GD2immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Results from this prospective study will aid in the development of future Phase II studies for this growing ultra high-risk patient population.
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Brian H
authors.initials: BH
authors.lastname: Kushner
authors.affiliation: Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center ; New York, NY USA.
authors.forename: Irina
authors.initials: I
authors.lastname: Ostrovnaya
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Irene Y
authors.initials: IY
authors.lastname: Cheung
authors.affiliation: Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center ; New York, NY USA.
authors.forename: Deborah
authors.initials: D
authors.lastname: Kuk
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Kim
authors.initials: K
authors.lastname: Kramer
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Shakeel
authors.initials: S
authors.lastname: Modak
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: Karima
authors.initials: K
authors.lastname: Yataghene
authors.affiliation: Department of Pediatrics; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
authors.forename: N K
authors.initials: NK
authors.lastname: Cheung
keywords: ASCT, autologous stem-cell transplantation; BM, bone marrow; CNS, central nervous system; CR, complete remission; GM-CSF, granulocyte-macrophage colony-stimulating factor; HAMA, human anti-mouse antibody; HR-NB: high-risk neuroblastoma; INRC, International Neuroblastoma Response Criteria; INRG, International Neuroblastoma Risk Group; MIBG, metaiodobenzylguanidine; MRD, minimal residual disease; OS, overall survival; PD, progressive disease; PFS, progression-free survival; VGPR, very good partial remission; anti-GD2 antibody; immunotherapy; mAb, monoclonal antibody; minimal residual disease; salvage; second remission